Bio-Techne Announces Publication of Data Demonstrating Additional Clinical Validation of its EPI Test in European Urology Journal Bio-Techne today announced the online publication of its second prospective US clinical validation study of the Exosome Diagnostics-branded ExoDx®...

About the EPI Test

ExoDx® Prostate(IntelliScore) (EPI) is the first exosomal urine-based liquid biopsy test, designed to risk stratify patients presenting for prostate biopsy. The test is a purely genomic test that examines the presence of three gene signatures known to be expressed in prostate cancer – SPDEF, ERG and PCA3. Visit epi.exosomedx.com to learn more.

About European Urology

European Urology is the premier specialist journal in the field of Urology and Nephrology. Publishing important, practice challenging manuscripts to educate readers and improve the care of patients. To keep up to date with the rapidly evolving world of medicine, the editorial team regularly review the journal's content, structure and mode of delivery. European Urology publishes peer-reviewed original articles, state of the art reviews and opinion piece editorials on a wide range of urological problems.

About Bio-Techne Corporation (NASDAQ: TECH )

Contact: Kim Kelderman , President, Diagnostics and Genomics Segment, 612-379-2956

SOURCE Bio-Techne Corporation